

ARD

Annals of the Rheumatic Diseases
The EULAR Journal

Editor

Leo van de Putte (Nijmegen)

Associate editors

Thomas Bardin (Paris)
Johannes Bijlsma (Utrecht)
Gerd Burmester (Berlin)
Bevrah Hahn (Los Angeles)
Frank Wollheim (Lund)
Anthony Woolf (Truro)

Methodological adviser

Paco Welsing (Nijmegen)

Editorial board

Martin Aringer (Vienna)
Paul Bacon (Birmingham)
Francis Berenbaum (Paris)
Maarten Boers (Amsterdam)
Dimitrios Boumpas (Heraklion)
Barry Bresnihan (Dublin)
Hillary Capell (Glasgow)
Maurizio Cutolo (Genova)
Gary Firestein (La Jolla San Diego)
Philippe Goupille (Tours)
Ellen Gravallese (Boston)
Wolfgang Gross (Bad Bramstedt)
Francis Guillemain (Nancy)
Gabriel Herrero-Beaumont (Madrid)
Frederic Houssiau (Brussels)
Tom Huizinga (Leiden)
Christian Jorgensen (Montpellier)
George Kollias (Athens)
Tore Kvien (Oslo)
Marjatta Leirisalo-Repo (Lund)
Frank Luijten (Leuven)
Hanns-Martin Lorenz (Heidelberg)

W Maslinski (Poland)
Marco Matucci Cerinic (Florence)
Kusuki Nishioka (Kanagawa)
Seza Özen (Ankara)
Thomas Pap (Magdeburg)
Eliseo Pascual Gómez (Alicante)
Leonardo Punzi (Padova)
Lars Rönnblom (Uppsala)
Blaž Rozman (Ljubljana)
Georg Schett (Vienna)
José Da Silva (Coimbra)
Hendrik Schulze-Koops (Erlangen)
Alex So (Lausanne)
Tuulikki Sokka (Nashville)
Deborah Symmons (Manchester)
Paul-Peter Tak (Amsterdam)
Alan Tyndall (Basel)
Athanasios Tzioufas (Athens)
Jiří Vencovsky (Praag)
Michael Ward (Bethesda)
Michael Weisman (Los Angeles)
Hasan Yazici (Istanbul)
Editor, *BMJ*

Advisory committee

Wim vd Berg (Nijmegen)
Stefano Bombardieri (Pisa)
Ferdinand Breedveld (Leiden)
Leslie Crofford (Michigan)
Jean-Michel Dayer (Geneva)
Mike Doherty (Nottingham)
Maxime Dougados (Paris)
John Edmonds (Sydney)
Paul Emery (Leeds)
Daniel Furst (Seattle)
Steffen Gay (Zurich)
Joachim Kalden (Erlangen)
Edward Keystone (Toronto)
Lars Klareskog (Stockholm)

Peter Lipsky (Dallas)
Stefan Lohmander (Lund)
Ravinder Maini (London)
Emilio Martin Mola (Madrid)
Haralampos Moutsopoulos (Athens)
James O'Dell (Omaha)
Karel Pavelka (Prague)
Josef Rovensky (Piestany)
Yehuda Shoenfeld (Tel-Hashomer)
Josef Smolen (Vienna)
Walther van Venrooy (Nijmegen)
Eric Veys (Gent)
Allan Wiik (Denmark)

Instructions to authors

All papers must be submitted via BenchPress at <http://submit-ard.bmjournals.com/>

Subscription information

See p iv


Copyright

© 2005 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*

Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at www.annrheumdis.com/misc/fora.shtml

Annals of the Rheumatic Diseases is published by BMJ Publishing Group, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Unwin Brothers, Woking

- Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



Macroscopic examination of the synovium before treatment with anti-TNF α . See p 497

contents ARD

Volume 64 Number 3 March 2005

Leader

345 Large scale evidence and replication: insights from rheumatology and beyond *J P A Ioannidis*

Review

347 Primary Sjögren's syndrome: new clinical and therapeutic concepts *M Ramos-Casals, A G Tzioufas, J Font*

Lesson of the month

355 Cervical complications of rheumatoid arthritis *M J Kauppi, A Barcelos, J A P da Silva*

Extended reports

359 Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors *T R D J Radstake, R van der Voort, M ten Brummelhuis, M de Waal Malefijt, M Looman, C G Figdor, W B van den Berg, P Barrera, G J Adema*

368 Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis *P L E M van Lent, P N Span, A W Sloetjes, T R D J Radstake, A W T van Lieshout, J J T M Heuvel, C G J Sweep, W B van den Berg*

375 Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography *E Naredo, G Bonilla, F Gamero, J Uson, L Carmona, A Laffon*

382 Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement *A Del Rosso, O Distler, A F Milia, C Emanuelli, L Ibbá-Manneschi, S Guiducci, M L Conforti, S Generini, A Pignone, S Gay, P Madeddu, M Matucci-Cerinic*

388 Effect of nitric oxide on mitochondrial respiratory activity of human articular chondrocytes *E Maneiro, M J López-Armada, M C de Andres, B Caramés, M A Martín, A Bonilla, P del Hoyo, F Galdo, J Arenas, F J Blanco*

396 Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis *A Boonen, R van den Heuvel, A van Tubergen, M Goossens, J L Severens, D van der Heijde, S van der Linden*

403 Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF α *C Eriksson, S Engstrand, K-G Sundqvist, S Rantapää-Dahlqvist*

408 Inhibition of TNF α during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF α blockade in rheumatoid arthritis *A W T van Lieshout, P Barrera, R L Smeets, G J Pesman, P L C M van Riel, W B van den Berg, T R D J Radstake*

**NEW
ONLINE
SUBMISSION**

**GO TO
WEBSITE**

**TO SUBMIT YOUR
MANUSCRIPT**

- 415 Effect of treatment of rheumatoid arthritis with infliximab on IFN γ , IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity *M Kawashima, P Miossec*
- 419 Galectin-3 is induced in rheumatoid arthritis synovial fibroblasts after adhesion to cartilage oligomeric matrix protein *M Neidhart, F Zaucke, R von Knoch, A Jüngel, B A Michel, R E Gay, S Gay*
- 425 Lower limb arterial incompressibility and obstruction in rheumatoid arthritis *I del Rincón, R W Haas, S Pogolian, A Escalante*
- 433 Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity *A M M Eijsbouts, F H J van den Hoogen, R F J M Laan, C G J Sweep, A R M M Hermus, L B A van de Putte*
- 438 Evidence for familial aggregation of hand, hip, and spine but not knee osteoarthritis in siblings with multiple joint involvement: the GARP study *N Riyazi, I Meulenbelt, H M Kroon, K H Runday, M-P Hellio le Graverand, F R Rosendaal, F C Breedveld, P E Slagboom, M Kloppenburg*
- 444 Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus *N Marto, M L Bertolaccini, E Calabuig, G R V Hughes, M A Khamashta*
- 449 A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis *L S Lohmander, D McKeith, O Svensson, M Malmenäs, L Bolin, A Kalla, G Genti, J Szechinski, C Ramos-Remus, for the STAR Multinational Study Group*
- 457 Distinct tumour necrosis factor α , interferon γ , interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis *B M Spriewald, O Witzke, R Wassmuth, R R Wenzel, M-L Arnold, T Philipp, J R Kalden*
- 462 Pathogenic role of anti- β 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of β 2-glycoprotein I binding to trophoblast cells and functional effects of anti- β 2-glycoprotein I antibodies in vitro *N Di Simone, E Raschi, C Testoni, R Castellani, M D'Asta, T Shi, S A Krilis, A Caruso, P L Meroni*
- 471 B cell MALT lymphoma diagnosed by labial minor salivary gland biopsy in patients screened for Sjögren's syndrome *N M Van Mello, S R Pillemer, P P Tak, V Sankar*
- 474 Genetic association analysis of the IGFBP7, ADAMTS3, and IL8 genes as the potential osteoarthritis susceptibility that maps to chromosome 4q *C Kawahara, T Forster, K Chapman, A Carr, J Loughlin*
- 477 DNA methylation is not likely to be responsible for aggrecan down regulation in aged or osteoarthritic cartilage *E Pöschl, A Fidler, B Schmidt, A Kallipolitou, E Schmid, T Aigner*
- 481 Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers *Y Allanore, D Borderie, C Meune, H Lemaréchal, S Weber, O G Ekindjian, A Kahan*
- 484 β Thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis *O Kowal-Bielecka, K Kowal, A Lewszuk, A Bodzenta-Lukaszyk, J Walecki, S Sierakowski*
- 487 Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis *V Pokorny, F McQueen, S Yeoman, M Merriman, A Merriman, A Harrison, J Highton, L McLean*
- 491 Radiographic progression in children with polyarticular juvenile rheumatoid arthritis: a pilot study *T Mason, A M Reed, A M Nelson, K B Thomas*
- 494 CNI-1493, an inhibitor of proinflammatory cytokines, retards cartilage destruction in rats with collagen induced arthritis *E Larsson, H E Harris, K Palmblad, B Månsson, T Saxne, L Klareskog*
- 497 Tumour necrosis factor α blockade in treatment resistant pigmented villonodular synovitis *E-J A Kroot, M C Kraan, T J M Smeets, M Maas, P P Tak, J M G W Wouters*

Concise reports

- 468 Analysis of the insertion/deletion related polymorphism within T cell antigen receptor β variable genes in primary Sjögren's syndrome *C A Lawson, I J Donaldson, S J Bowman, J Shefta, A W Morgan, A Gough, J D Isaacs, B Griffiths, P Emery, C T Pease, A W Boylston*
- 500 Recurrent limp in a young boy *F Falcini, T Giani, A Lippi, M Resti, G Simonini*
- 501 Finger joint swellings in a teenager: juvenile rheumatoid arthritis or a psychiatric disorder? *B Ostendorf, C Iking-Konert, M Cohnen, M Schneider*

Letters

- 502 Worse patient VAS occurs at weeks 7 and 8 after infliximab infusions *N Shenker, R Haigh, A Clarke*
- 503 Glucocorticoid receptor polymorphisms in Korean patients with rheumatoid arthritis *E B Lee, J Y Kim, Y J Lee, Y W Song*
- 504 Tenascin-X: a candidate gene for benign joint hypermobility syndrome and hypermobility type Ehlers-Danlos syndrome? *M C Zweers, M Kucharekova, J Schalkwijk*
- 505 Multiple venous thrombosis in SAPHO syndrome *T Kawabata, Y Morita, A Nakatsuka, H Kagawa, M Kawashima, T Sei, M Yamamura, H Makino*
- 506 A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis *P V Gardiner, A L Bell, A J Taggart, G Wright, F Kee, A Smyth, R McKane, J Lee, M E Rooney, E Whitehead*
- 507 No improvement in a pilot study of tai chi exercise in rheumatoid arthritis *T Uhlig, C Larsson, A-G Hjorth, S Ødegård, T K Kvien*
- 509 Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab *F Broussais, M Kawashima, H Marotte, P Miossec*
- 510 Muscarinic acetylcholine receptor autoantibodies in patients with Sjögren's syndrome *Y Naito, I Matsumoto,*

E Wakamatsu, D Goto, T Sugiyama, R Matsumura, S Ito, A Tsutsumi, T Sumida

.....
Matters arising

- 512 Is IV infliximab better than IV methylprednisolone for the treatment of patients with RA when methotrexate fails? *M D Smith; P Durez, T A Nzeusseu, B R Lauwerys, D H Manicourt, J-P Devogelaer, F A Houssiau, P Verschueren, R Westhovens*
- 512 Antimicrobial treatment for *Chlamydia* induced reactive arthritis *J D Carter, J Valeriano, F B Vasey; J S H Gaston, T K Kvien*
- 513 Is Behçet's syndrome associated with infection? *A P Rozin; G Hatemi, H Yazici*
- 515 Different threshold for prolactin response to hypoglycaemia in patients with rheumatoid arthritis? *R Imrich, M Vigas, J Rovensky; A M M Eijsbouts on behalf of the other authors*
- 516 A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable? *M K Reinders, E N van Roon, J R B J Brouwers, T L Th A Jansen; A-K Tausche, H E Schröder*
-

- 516 Correction
- 516 Forthcoming events



This logo indicates an article that was published online first ahead of print